Pharma M&A Passed $200B In 2014, Primed For More In 2015
This article was originally published in The Tan Sheet
Executive Summary
The pharma industry in 2014 products its biggest M&A year in recent history, though it may be remembered equally for sagas and upsets that failed to materialize into finalized deals. Actavis was the most aggressive acquirer, buying Forest and Allergan for a total of $89.3 billion in the two most expensive deals of the year.
You may also be interested in...
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.